International Multicenter Clinical Real World Study
SungenBio and Peking University Medical Department cooperated in the Multi-Center Clinical Real-World Study of vitamin K2, vitamin D3, calcium and nattokinase red yeast compound, and analyzed the physiological effects and clinical value of the product on the human body through three-way data comparison.
Program design: Peking University School of Medicine
Execution: Guangdong Sungen Biotechnology Co., Ltd.
Support: Shenyang Pharmaceutical University, Dalian Medical University, Harbin Medical University, North Sichuan Medical College
· Clinical experience cases: 1560 (731 males, 829 females, average age 65 years)
· Clinical experience cycle: taking vitamin K2, vitamin D3, calcium complex, 12 months
· Main evaluation indicators: bone density index, subjective feeling index, behavioral signs, etc.
Clinical experience results
Indicators | Number of observations | Progressive cases | Effective cases | Number of recovery | Number of invalid cases | Total efficiency (%) |
---|---|---|---|---|---|---|
Bone density | 1560 | 405 | 930 | 152 | 152 | 95.3% |
Typical case: bone density increased from -5.6 to +0.53
Indicators | Number of observations | Effective cases | Number of recovery | Number of invalid cases | Total efficiency (%) |
---|---|---|---|---|---|
joint pain | 768 | 172 | 551 | 45 | 94.1% |
Obstructed activity | 257 | 68 | 172 | 27 | 89.5% |
Muscle weakness | 194 | 61 | 121 | 12 | 93.8% |
Conclusion:
· Increase bone mineral density
—95.3% total effective rate.
· Improve joint pain
—94.1% total effective rate.
· Improve Obstructed activity
—89.5% total effective rate.
· Improve Muscle weakness
—93.8% total effective rate.
· Distribution of clinical experience population: 2875 (1252 males, 1623 females, average age 66 years)
· Clinical experience cycle: Taking nattokinase red yeast compound, 12 months
· Main evaluation indicators: morphological indicators, biochemical measurement indicators, subjective feeling indicators, behavioral signs, mental activity indicators, etc.
Clinical Experience Results
Conclusion:
· The total effective rate of carotid plaque improvement is 91.3%, and the proportion of plaque disappeared is as high as 21.3%.
· The varicose vein improvement rate is 96%
· Effectively improve the symptoms of vascular wall thickening, the total effective rate is 94.6%
Blood Lipid Indicators
Conclusion:
· Total cholesterol is significantly reduced with a total effective rate of 89.2%
· The total triglyceride is significantly reduced with a total effective rate of 70.52%.
· Low-density lipoprotein cholesterol is significantly reduced with a total effective rate of 96.6%
· High-density lipoprotein cholesterol is significantly elevated with a total effective rate of 76.9%.
Subjective Perception Indicators
Conclusion: The subjective perception indicators of subjects are significantly improved, and the total improvement rate is over 80%.
Cardiac Function and Stroke Sequela Indicators
Conclusion: The total improvement in cardiac function and stroke sequelae was over 86.3%.
Vitamin K2 Research Fund Projects
SungenBio Vitamin K2 Research Fund was formally established at the China Scientific Nutrition Conference in May 2017. It collects vitamin K2 related research projects that have important scientific significance, application value, and feasibility through global open tendering process,bringing new development and breakthrough for international vitamin K2 research field.
Units | Projects |
---|---|
North Sichuan Medical College | The Preventive Effect of Vitamin K2 on Vascular Calcification in Maintenance Hemodialysis Patients |
Harbin Medical University | Study on The Health Effects of Vitamin K2 on Bone and Skeletal Muscles |
Harbin Medical University | Study on the Relationship between Vitamin K2 and Fundus Disease, Diabetes and Cardiovascular Diseases |
China Nutrition and Health Food Association | Determination of Vitamin K2 in Foods |
Shenyang Pharmaceutical University | Effect of Vitamin K2 (MK7) on Tumor |
Dalian Medical University | Research on the Effect of Vitamin K2 on Coronary Atherosclerosis |